HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.
XNK's presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye's homepage.
XNK's presentation will be followed by a short Q&A session.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications. The most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma. Other programs include XNK02 in acute myeloid leukemia, currently in preclinical studies in collaboration with MD Anderson Cancer Center and the Karolinska University Hospital, XNK03 in bladder cancer, currently in preclinical studies in collaboration with the Karolinska University Hospital and XNK04 in liver cancer in collaboration with a global pharma company. XNK's efforts are supported by a dedicated team that includes world-renowned NK cell experts and an approved in-house GMP facility. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.
The following files are available for download:
XNK Therapeutics to present at Redeye Regenerative Medicine Cell Therapy event | |
https://news.cision.com/xnk-therapeutics-ab/i/johan-liwing,c3265295 | Johan Liwing |
SOURCE XNK Therapeutics AB